Multiple ascending dose study with Memogain.
- Conditions
- Healthy volunteer studie, though drug may ameliorate Alzheimer's Disease symptoms.-Keywords: Galantamine, Alzheimer, Memogain, NeuroCart
- Registration Number
- NL-OMON23253
- Lead Sponsor
- eurodyn Life Sciences Inc.
- Brief Summary
http://www.alzheimersanddementia.com/article/S1552-5260%2814%2901257-6/abstract
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 48
1. Healthy male or postmenopausal female subjects, aged 65 years and over. Healthy status is defined by the absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead electrocardiogram (ECG), haematology, blood chemistry, and urinalysis;
2. Body Mass Index (BMI) between 18 kg/m² and 30 kg/m², inclusive, and with a minimum weight of 50 kg;
1. Legal incapacity or inability to understand or comply with the requirements of the study;
2. Clinically relevant history of abnormal physical or mental health interfering with the study as determined by medical history taking and physical examinations obtained during the screening visit and/or at the start of the first study day for each period as judged by the investigator;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.